financetom
Business
financetom
/
Business
/
NASA trims Boeing Starliner contract, makes last two missions optional
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NASA trims Boeing Starliner contract, makes last two missions optional
Nov 24, 2025 11:19 AM

Nov 24 (Reuters) - NASA and Boeing ( BA ) are revising

the Starliner spacecraft contract to reduce the number of

missions from six to four, the U.S. space agency said in a

statement on Monday.

The original $4.5 billion contract, awarded to Boeing ( BA ) under

NASA's Commercial Crew Program, envisioned six

post-certification operational flights of the Starliner capsule.

With the latest modification, NASA has designated the

remaining two flights as optional.

The Starliner program has been dogged for years by

delays, technical faults and cost overruns.

The next Starliner mission will be uncrewed, NASA said,

marking the third such test in a development effort that has

cost Boeing ( BA ) more than

$2 billion

since 2016.

Propulsion system issues on the capsule during its most

recent mission last year

forced

its debut crew to remain on the International Space Station

for roughly nine months.

The next mission, known as Starliner-1, will deliver

cargo to the International Space Station, NASA added. Boeing ( BA ) and

NASA are targeting no earlier than April 2026 for the flight.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Nov 17, 2025
02:58 PM EST, 11/17/2025 (MT Newswires) -- Jones Lang LaSalle ( JLL ) is set to benefit from improving industry tailwinds amid attractive valuation after its Q3 results, UBS Securities said in a Sunday note. The report pointed to an outlook downgrade for its Real Estate Management Services segment for the next several quarters while Q3 margin expansion disappointed, similar...
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Nov 17, 2025
Jazz Pharmaceuticals Plc ( JAZZ ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). What Happened: When compared to the control group that received trastuzumab...
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Nov 17, 2025
03:04 PM EST, 11/17/2025 (MT Newswires) -- Liberty Defense Holdings ( LDDFF ) shares were up near 14% on Monday after it received a competitive bid award for three HEXWAVE walkthrough screening systems at a U.S. State Capitol complex in the Northeast. The company said the systems will support security screening for officials, employees, and visitors across two high-traffic buildings....
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Nov 17, 2025
02:46 PM EST, 11/17/2025 (MT Newswires) -- Target ( TGT ) is likely to post soft Q3 on Wednesday with comparable sales down about 2% and could narrow its fiscal 2025 earnings per share guidance toward the low end of its $7 to $9 range, Oppenheimer said Monday in a pre-results report. Oppenheimer said it added conservatism to its Q4...
Copyright 2023-2025 - www.financetom.com All Rights Reserved